Wells Fargo & Company MN Has $185,000 Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Wells Fargo & Company MN increased its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 51.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,786 shares of the company’s stock after purchasing an additional 5,682 shares during the quarter. Wells Fargo & Company MN’s holdings in Stoke Therapeutics were worth $185,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Geode Capital Management LLC lifted its position in shares of Stoke Therapeutics by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 877,095 shares of the company’s stock worth $9,677,000 after purchasing an additional 6,264 shares in the last quarter. Norges Bank acquired a new stake in shares of Stoke Therapeutics in the 4th quarter valued at approximately $3,472,000. JPMorgan Chase & Co. raised its position in shares of Stoke Therapeutics by 29.2% in the 4th quarter. JPMorgan Chase & Co. now owns 19,964 shares of the company’s stock valued at $220,000 after acquiring an additional 4,512 shares during the period. EntryPoint Capital LLC bought a new position in Stoke Therapeutics during the 4th quarter worth approximately $353,000. Finally, KLP Kapitalforvaltning AS acquired a new position in Stoke Therapeutics during the fourth quarter valued at approximately $63,000.

Stoke Therapeutics Stock Performance

NASDAQ:STOK opened at $9.09 on Friday. The stock has a 50-day simple moving average of $7.99 and a 200 day simple moving average of $10.09. Stoke Therapeutics, Inc. has a 52-week low of $5.35 and a 52-week high of $17.58. The company has a market cap of $496.01 million, a PE ratio of -4.33 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The company had revenue of $22.61 million during the quarter, compared to analysts’ expectations of $4.20 million. On average, research analysts predict that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the transaction, the director now owns 148,253 shares of the company’s stock, valued at $1,285,353.51. The trade was a 6.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Barry Ticho sold 3,884 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the sale, the insider now directly owns 63,962 shares of the company’s stock, valued at approximately $554,550.54. The trade was a 5.72 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 16,532 shares of company stock valued at $143,332 in the last three months. 11.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $47.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Chardan Capital reiterated a “buy” rating and set a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, April 9th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $25.60.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.